09:36 AM EDT, 08/11/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Monday that US Food & Drug Administration approved an investigational new drug application for the phase 2a clinical trial of intranasal foralumab in patients with multiple system atrophy.

The phase 2a trial is a six-month, open-label clinical trial designed to evaluate the effects of intranasal foralumab on microglial activation, clinical outcomes, and safety in patients with multiple system atrophy, the company said.

Multiple system atrophy is a progressive neurodegenerative disorder that affects both the central and autonomic nervous systems.

Shares of Tiziana Life Sciences ( TLSA ) were up 8% in recent Monday trading activity.